Log in

NASDAQ:CFRXContraFect Stock Price, Forecast & News

$5.17
-0.14 (-2.64 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.07
Now: $5.17
$5.26
50-Day Range
$5.31
MA: $6.26
$7.48
52-Week Range
$2.69
Now: $5.17
$13.40
Volume288,028 shs
Average Volume293,282 shs
Market Capitalization$79.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Read More
ContraFect logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$0.62 per share
Book Value$1.01 per share

Profitability

Net Income$-12,790,000.00

Miscellaneous

Employees20
Market Cap$79.26 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

How has ContraFect's stock been impacted by COVID-19 (Coronavirus)?

ContraFect's stock was trading at $6.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CFRX shares have decreased by 25.7% and is now trading at $5.17. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ContraFect?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ContraFect.

When is ContraFect's next earnings date?

ContraFect is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for ContraFect.

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) issued its earnings results on Friday, May, 15th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.10. View ContraFect's earnings history.

When did ContraFect's stock split? How did ContraFect's stock split work?

ContraFect's stock reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CFRX?

2 brokerages have issued twelve-month target prices for ContraFect's shares. Their forecasts range from $15.00 to $22.00. On average, they expect ContraFect's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 257.8% from the stock's current price. View analysts' price targets for ContraFect.

Has ContraFect been receiving favorable news coverage?

Media stories about CFRX stock have been trending very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ContraFect earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutContraFect.

Are investors shorting ContraFect?

ContraFect saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 736,500 shares, an increase of 25.2% from the April 30th total of 588,200 shares. Based on an average daily volume of 182,100 shares, the days-to-cover ratio is currently 4.0 days. Currently, 6.1% of the shares of the company are sold short. View ContraFect's Current Options Chain.

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Verastem (VSTM), Novavax (NVAX), Gilead Sciences (GILD), Cidara Therapeutics (CDTX), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Vaxart (VXRT) and Crispr Therapeutics (CRSP).

Who are ContraFect's key executives?

ContraFect's management team includes the following people:
  • Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
  • Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
  • Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a variety of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (19.89%), Fosun International Ltd (4.86%), White Pine Capital LLC (0.96%), Oracle Investment Management Inc. (0.84%), Geode Capital Management LLC (0.68%) and Minot Wealth Management LLC (0.45%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger. View institutional ownership trends for ContraFect.

Which major investors are selling ContraFect stock?

CFRX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Fosun International Ltd, Oracle Investment Management Inc., White Pine Capital LLC, Minot Wealth Management LLC, Geode Capital Management LLC, and BlackRock Inc.. View insider buying and selling activity for ContraFect.

Which major investors are buying ContraFect stock?

CFRX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Spark Investment Management LLC, and Jane Street Group LLC. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff, and Michael Messinger. View insider buying and selling activity for ContraFect.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $5.17.

How big of a company is ContraFect?

ContraFect has a market capitalization of $79.26 million. The biotechnology company earns $-12,790,000.00 in net income (profit) each year or $1.11 on an earnings per share basis. ContraFect employs 20 workers across the globe.

What is ContraFect's official website?

The official website for ContraFect is www.contrafect.com.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.